Purpose: The accrual of the first clinical trial using Cs-131 for permanent brachytherapy
to treat early stage prostate cancer is 80% complete. Cesium has come into widespread
use; the clinical results of this trial are mature enough to be of immediate, important
practical use to practitioners.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
OR-1 Presentation Time: 9:00 AM
Footnotes
This work was supported by Isoray Medical, manufacturers of the source type used in the study.
Identification
Copyright
© 2007 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
